Table 1 Demographic and baseline characteristics of patients with NPC who were treated with famitinib
Variables | Patients (n = 20) |
|---|---|
Age, years | |
 Median (IQR) | 43 (39–48) |
 Range | 26–56 |
 Male sex | 18 (80%) |
ECOG | |
 0 | 1 (5%) |
 1 | 19 (95%) |
 Histology, WHO type III | 20 (100%) |
Tumour stage | |
 T1 | 1 (5%) |
 T2 | 3 (15%) |
 T3 | 13 (65%) |
 T4 | 3 (15%) |
Node stage | |
 N1 | 2 (10%) |
 N2 | 13 (65%) |
 N3 | 5 (25%) |
Clinical stage | |
 III | 12 (60%) |
 IVa | 3 (15%) |
 IVb | 5 (25%) |
EBV DNA, | |
 ≥ 4000 copy/ml | 10 (50%) |
VCA-IgA | |
 ≥ 1:80 | 15 (75%) |
EA-IgA | |
 ≥ 1:10 | 13 (65%) |
Smokinga | |
 Yes | 9 (45%) |
Family history of NPC | |
 Yes | 3 (15%) |